Odyssey Therapeutics, Inc.
NASDAQ:ODTXBiotechnology
-$0.01 today
- Market cap
- $912.33M
- Beta
- 0.00
Volume 0.37M
Average 0.43M
ODTX Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Operating Expenses history
Currency unavailable · from the income statement
No Operating Expenses data reported for this period type.
Operating Expenses vs competitors
How ODTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $465.53M USD | +1.6% | +58.0% | 6292.6% |
| LTM Sep 2026 | $295.42M USD | +75.4% | -24.2% | 326.5% | |
| LTM Mar 2026 | $229.74M USD | +420.0% | +71.3% | 98.9% | |
| LTM Jun 2026 | $223.24M USD | +20.5% | +8.7% | 79.2% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $182.95M USD | +45.3% | +132.3% | — |
| LTM Mar 2026 | $109.61M USD | +8.6% | -4.8% | — | |
| LTM Mar 2026 | $86.87M USD | -40.0% | -8.6% | 1038.2% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | €48.02M EUR | +54.0% | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ODTX) | — | +32.9% | +8.7% | 326.5% | |
Competitors are the stored peer set for ODTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Odyssey Therapeutics, Inc.
NASDAQ:ODTX
Intrinsic Alpha fair value
Locked
Current Price
$18.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.